These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 27461460)

  • 21. [Effects of traditional Chinese medicine on CD4 + T cell counts and HIV viral loads during structured treatment interruption in highly active antiretroviral therapy].
    Zhao HX; Zhang FJ; Han N; Lan MD; Yao J; Liu ZY; Lu LH; Wei HS
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2006 Oct; 28(5):658-61. PubMed ID: 17121226
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Factors influencing increases in CD4 cell counts of HIV-positive persons receiving long-term highly active antiretroviral therapy.
    Smith CJ; Sabin CA; Youle MS; Kinloch-de Loes S; Lampe FC; Madge S; Cropley I; Johnson MA; Phillips AN
    J Infect Dis; 2004 Nov; 190(10):1860-8. PubMed ID: 15499544
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of injecting drug use on response to highly active antiretroviral treatment in HIV-1-infected patients: a nationwide population-based cohort study.
    Larsen MV; Omland LH; Gerstoft J; Røge BT; Larsen CS; Pedersen G; Obel N; Kronborg G
    Scand J Infect Dis; 2010 Dec; 42(11-12):917-23. PubMed ID: 20840000
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The CD4 slope can be a predictor of immunologic recovery in advanced HIV patients: a case-control study.
    Kim KH; Yi J; Lee SH
    Korean J Intern Med; 2015 Sep; 30(5):705-13. PubMed ID: 26354065
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term effects of highly active antiretroviral therapy in pretreated, vertically HIV type 1-infected children: 6 years of follow-up.
    Resino S; Resino R; Micheloud D; Gurbindo Gutiérrez D; Léon JA; Ramos JT; Ciria L; de José I; Mellado J; Muñoz-Fernández A;
    Clin Infect Dis; 2006 Mar; 42(6):862-9. PubMed ID: 16477566
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Kaposi sarcoma herpes virus antibody response and viremia following highly active antiretroviral therapy in the Swiss HIV Cohort study.
    Sullivan SG; Hirsch HH; Franceschi S; Steffen I; Amari EB; Mueller NJ; Magouras I; Biggar RJ; Rickenbach M; Clifford GM;
    AIDS; 2010 Sep; 24(14):2245-52. PubMed ID: 20543658
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term follow-up of asymptomatic HIV-infected patients who discontinued antiretroviral therapy.
    Fernández Guerrero ML; Rivas P; Molina M; Garcia R; De Górgolas M
    Clin Infect Dis; 2005 Aug; 41(3):390-4. PubMed ID: 16007538
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transient lowering of the viral set point after temporary antiretroviral therapy of primary HIV type 1 infection.
    Steingrover R; Garcia EF; van Valkengoed IG; Bekker V; Bezemer D; Kroon FP; Dekker L; Prins M; de Wolf F; Lange JM; Prins JM
    AIDS Res Hum Retroviruses; 2010 Apr; 26(4):379-87. PubMed ID: 20377419
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effects of highly active antiretroviral therapy (HAART) of stavudine, lamivudine and nevirapine on the CD4 lymphocyte count of HIV-infected Africans: the Nigerian experience.
    Erhabor O; Ejele OA; Nwauche CA
    Niger J Clin Pract; 2006 Dec; 9(2):128-33. PubMed ID: 17319344
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Patterns, predictors, and consequences of initial regimen type among HIV-infected women receiving highly active antiretroviral therapy.
    Golub ET; Benning L; Sharma A; Gandhi M; Cohen MH; Young M; Gange SJ
    Clin Infect Dis; 2008 Jan; 46(2):305-12. PubMed ID: 18171267
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term survival and immuno-virological response of African HIV-1-infected children to highly active antiretroviral therapy regimens.
    Rouet F; Fassinou P; Inwoley A; Anaky MF; Kouakoussui A; Rouzioux C; Blanche S; Msellati P;
    AIDS; 2006 Nov; 20(18):2315-9. PubMed ID: 17117017
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of maintaining highly active antiretroviral therapy on AIDS events among patients with late-stage HIV infection and inadequate response to therapy.
    Gandhi T; Wei W; Amin K; Kazanjian P
    Clin Infect Dis; 2006 Mar; 42(6):878-84. PubMed ID: 16477568
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improved outcomes with earlier initiation of highly active antiretroviral therapy among human immunodeficiency virus-infected patients who achieve durable virologic suppression: longer follow-up of an observational cohort study.
    Sterling TR; Chaisson RE; Keruly J; Moore RD
    J Infect Dis; 2003 Dec; 188(11):1659-65. PubMed ID: 14639536
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A randomized clinical trial of community-based directly observed therapy as an adherence intervention for HAART among substance users.
    Macalino GE; Hogan JW; Mitty JA; Bazerman LB; Delong AK; Loewenthal H; Caliendo AM; Flanigan TP
    AIDS; 2007 Jul; 21(11):1473-7. PubMed ID: 17589194
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety of long-term interruption of successful antiretroviral therapy: the ATHENA cohort study.
    Wit FW; Blanckenberg DH; Brinkman K; Prins JM; van der Ende ME; Schneider MM; Mulder JW; de Wolf F; Lange JM;
    AIDS; 2005 Feb; 19(3):345-8. PubMed ID: 15718848
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Virologic response to potent antiretroviral therapy and modeling of HIV dynamics in early pediatric infection.
    Palumbo P; Wu H; Chadwick E; Ruan P; Luzuriaga K; Rodman J; Yogev R;
    J Infect Dis; 2007 Jul; 196(1):23-9. PubMed ID: 17538879
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Influence of prior antiretroviral experience on adherence and responses to new highly active antiretroviral therapy regimens.
    Horberg M; Silverberg M; Hurley L; Delorenze G; Quesenberry C
    AIDS Patient Care STDS; 2008 Apr; 22(4):301-12. PubMed ID: 18338961
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression.
    Moore RD; Keruly JC
    Clin Infect Dis; 2007 Feb; 44(3):441-6. PubMed ID: 17205456
    [TBL] [Abstract][Full Text] [Related]  

  • 39. T-cell response of advanced aids patients after highly active antiretroviral therapy.
    Wang AX; Li TS; Cao YZ; Han Y; Qiu ZF; Xie J
    Chin Med Sci J; 2005 Dec; 20(4):223-5. PubMed ID: 16422247
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictive factors for immunological and virological endpoints in Thai patients receiving combination antiretroviral treatment.
    Srasuebkul P; Ungsedhapand C; Ruxrungtham K; Boyd MA; Phanuphak P; Cooper DA; Law MG
    HIV Med; 2007 Jan; 8(1):46-54. PubMed ID: 17305932
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.